When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

3. Medicare targets popular weight loss drugs Ozempic, Wegovy ...

   www.aol.com/medicare-targets-popular-weight-loss...

   Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

4. Some drugmakers to cap cost of asthma inhalers at $35 a month

   www.aol.com/news/drugmakers-cap-cost-asthma...

   Kiowa Rix, 27, of Warren, Michigan, found herself with a $500 out-of-pocket price tag for her son Lucas’ inhaler — Flovent, from GSK — in February, when her insurance stopped covering the ...

5. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

6. Boehringer to cut out-of-pocket costs for inhalers to $35 - AOL

   www.aol.com/news/boehringer-cut-pocket-costs...

   (Reuters) - Boehringer Ingelheim will reduce out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma to $35 per month starting June 1, the German drugmaker ...

7. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...